Beam Therapeutics Inc (BEAM) Stock Price, Quote & News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 327 8775

Website: beamtx.com

Address:

238 Main Street, Cambridge, United States

LiquidThetaLEAPS Oct. 4 at 9:11 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BEAM Current Share Price: $25.75 Contracts: $BEAM January 15, 2027 $27 Calls Scale in: $7.21- $8.81 Scale out: $11.21-$14.42 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

SweepCastApp Oct. 4 at 6:11 AM

$BEAM: Unusual Options Activity Alerted CALL flow observed 50x contracts at Strike price of $17 Exp on 02/20/2026 with Premium of $47K and showing BEARISH Sentiment

0 · Reply

Elamenape2 Oct. 3 at 6:13 PM

$BEAM

0 · Reply

MoonCowBoy Oct. 2 at 11:39 PM

$BEAM $HD $TD $MIMI <

0 · Reply

3DBuilds Oct. 2 at 7:34 PM

$EDIT $CRSP $BEAM $NTLA $BMY

0 · Reply

EingeLTrade Oct. 2 at 7:18 PM

$BEAM

0 · Reply

LiquidThetaLEAPS Oct. 2 at 7:04 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BEAM Current Share Price: $24.13 Contracts: $BEAM January 15, 2027 $25 Calls Scale in: $7.31- $8.94 Scale out: $11.38-$14.62 Can Easily Capture: 60% ROI Blended DTE: 471 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

THE_Monkey_Banana_Genius Oct. 2 at 5:41 PM

$CRSP $NTLA $PRME long all + $BEAM

1 · Reply

Megalodon76 Oct. 2 at 4:55 PM

$BEAM Damn it! please short this down so i can cover....

0 · Reply

Bombaata Oct. 2 at 4:13 PM

$MXCT $CRBU $PRME $BEAM $CRSP so exciting you had to SPAM 4 other boards... must be a SCAM STOCK

1 · Reply

Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 9, 2025, 4:51 AM EDT - 25 days ago

Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 3, 2025, 8:38 PM EDT - 4 weeks ago

Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 25, 2025, 7:00 AM EDT - 5 weeks ago

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Aug 14, 2025, 7:00 AM EDT - 7 weeks ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Aug 5, 2025, 7:00 AM EDT - 2 months ago

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 20, 2025, 10:07 AM EDT - 3 months ago

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

Jun 13, 2025, 7:00 AM EDT - 4 months ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Jun 3, 2025, 7:00 AM EDT - 4 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

May 29, 2025, 4:01 PM EDT - 4 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 14, 2025, 9:30 AM EDT - 5 months ago

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 13, 2025, 7:00 AM EDT - 5 months ago

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 12, 2025, 4:01 PM EDT - 5 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 6, 2025, 7:00 AM EDT - 5 months ago

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 5, 2025, 7:00 AM EDT - 6 months ago

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Mar 31, 2025, 2:25 PM EDT - 6 months ago

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

MRNA

Mar 27, 2025, 4:01 PM EDT - 6 months ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Mar 21, 2025, 1:13 PM EDT - 7 months ago

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy

Mar 10, 2025, 9:07 AM EDT - 7 months ago

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Mar 10, 2025, 6:01 AM EDT - 7 months ago

Beam Therapeutics Announces Pricing of Underwritten Offering

Mar 10, 2025, 6:00 AM EDT - 7 months ago

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Feb 25, 2025, 7:00 AM EST - 7 months ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Feb 24, 2025, 7:00 AM EST - 7 months ago

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Jan 30, 2025, 7:00 AM EST - 8 months ago

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:00 AM EST - 9 months ago

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Jan 13, 2025, 7:00 AM EST - 9 months ago

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Dec 8, 2024, 1:45 PM EST - 10 months ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Dec 7, 2024, 11:30 AM EST - 10 months ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Dec 6, 2024, 7:00 AM EST - 10 months ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Dec 4, 2024, 7:00 AM EST - 10 months ago

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Nov 12, 2024, 4:01 PM EST - 11 months ago

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Nov 7, 2024, 2:25 PM EST - 11 months ago

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 5, 2024, 11:54 AM EST - 11 months ago

Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 6:30 AM EST - 11 months ago

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Aug 6, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Jul 15, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces Transition of Chief Financial Officer

Jun 26, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 14, 2024, 3:00 AM EDT - 1 year ago

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

May 30, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

May 14, 2024, 4:00 PM EDT - 1 year ago

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

May 8, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

May 7, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

Mar 26, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Feb 28, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

Feb 27, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

Feb 5, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 8, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

Jan 2, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 14, 2023, 6:30 AM EST - 1 year ago

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

LiquidThetaLEAPS Oct. 4 at 9:11 PM

0 · Reply

SweepCastApp Oct. 4 at 6:11 AM

$BEAM: Unusual Options Activity Alerted CALL flow observed 50x contracts at Strike price of $17 Exp on 02/20/2026 with Premium of $47K and showing BEARISH Sentiment

0 · Reply

Elamenape2 Oct. 3 at 6:13 PM

$BEAM

0 · Reply

MoonCowBoy Oct. 2 at 11:39 PM

$BEAM $HD $TD $MIMI <

0 · Reply

3DBuilds Oct. 2 at 7:34 PM

$EDIT $CRSP $BEAM $NTLA $BMY

0 · Reply

EingeLTrade Oct. 2 at 7:18 PM

$BEAM

0 · Reply

LiquidThetaLEAPS Oct. 2 at 7:04 PM

0 · Reply

THE_Monkey_Banana_Genius Oct. 2 at 5:41 PM

$CRSP $NTLA $PRME long all + $BEAM

1 · Reply

Megalodon76 Oct. 2 at 4:55 PM

$BEAM Damn it! please short this down so i can cover....

0 · Reply

Bombaata Oct. 2 at 4:13 PM

$MXCT $CRBU $PRME $BEAM $CRSP so exciting you had to SPAM 4 other boards... must be a SCAM STOCK

1 · Reply

Mindegap Oct. 2 at 2:57 PM

$MXCT Waiting, waiting for the rest of the world to realize how imporant $MXCT is across all gene editing platforms. $CRBU $PRME $BEAM $CRSP

3 · Reply

MoonCowBoy Oct. 2 at 12:18 PM

Caught a few of @CarlosRivera_’s plays recently dude’s been on point! If you're into trading, he's worth a follow💯 watching $FSLY $BEAM $ZENA $VNET

0 · Reply

SweepCastApp Oct. 2 at 10:34 AM

$BEAM: Unusual Options Activity Alerted CALL flow observed 500x contracts at Strike price of $26 Exp on 02/20/2026 with Premium of $175K and showing BEARISH Sentiment

0 · Reply

Mcnulty_jimmy Oct. 1 at 5:09 PM

$ABCL is taking off today. I think biotech as a whole is on the cusp of something big $XBI $PRME $NTLA $BEAM

0 · Reply

THE_Monkey_Banana_Genius Oct. 1 at 1:43 PM

$CRSP $NTLA $PRME $BEAM

0 · Reply

LiquidThetaLEAPS Sep. 30 at 3:13 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BEAM Current Share Price: $23.72 Contracts: $BEAM January 15, 2027 $25 Calls Scale in: $7.04- $8.61 Scale out: $10.96-$14.09 Can Easily Capture: 60% ROI Blended DTE: 473 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Stocktud Sep. 30 at 1:20 PM

$BEAM $IBRX https://elite.finviz.com/news/171343/immunitybios-ibrx-anktiva-shows-survival-gains-in-lung-cancer-patients

0 · Reply

CashCashBaby Sep. 30 at 1:13 PM

$IBRX $BEAM Know what you havehttps://elite.finviz.com/news/171343/immunitybios-ibrx-anktiva-shows-survival-gains-in-lung-cancer-patients

0 · Reply

highnihilism Sep. 30 at 7:42 AM

$BEAM Beam Therapeutics: 161 trades, $382K vs $266K avg (1.44x). $319K calls / $63K puts. 95% single-leg. $SMCX Defiance Target 2X Long Smci ETF: 343 trades, $566K vs $1.73M avg (0.33x). $317K calls / $249K puts. 60% single-leg. $MTCH Match Group: 438 trades, $401K vs $1.06M avg (0.38x). $316K calls / $85K puts. 42% single-leg. $SYF Synchrony Financial: 697 trades, $754K vs $438K avg (1.72x). $316K calls / $438K puts. 94% single-leg.

0 · Reply

PDM5 Sep. 29 at 7:48 PM

$BEAM when is this thing going to pop? Have been in since early 2022 but have fallen out of the loop recently...

0 · Reply

SweepCastApp Sep. 29 at 3:17 PM

$BEAM: Unusual Options Activity Alerted CALL flow observed 50x contracts at Strike price of $20 Exp on 02/20/2026 with Premium of $29K and showing BEARISH Sentiment

0 · Reply

LiquidThetaLEAPS Sep. 29 at 12:37 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BEAM Current Share Price: $22.97 Contracts: $BEAM January 15, 2027 $25 Calls Scale in: $6.95- $8.50 Scale out: $10.81-$13.90 Can Easily Capture: 60% ROI Blended DTE: 474 Days | Join Elites here: https://liquidtheta.com

0 · Reply

Market Cap	2.60B
Revenue (ttm)	63.52M
Net Income (ttm)	-376.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-593.10%
Debt to Equity Ratio	0.00

Volume	2,254,500
Avg Vol	2,607,402
Day's Range	N/A - N/A
Shares Out	101.16M
Stochastic %K	89%
Beta	2.25
Analysts	Strong Sell
Price Target	$43.80